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ABSTRACT  
 
Imipress Tablet 25 mg is one of the products of Chemical Company of Malaysia, 
Duopharma Sdn. Bhd, CCMD. The Active Pharmaceutical Ingredient is Imipramine 
Hydrochloride which contains 25 mg per tablet. Method validation was carried out in terms 
of specificity (force degradation), placebo analysis, linearity and range, accuracy, precision 
(repeatability and intermediate precision), robustness and solution stability. This method 
has been shown to be linear, accurate, precise, rugged and robust. The HPLC method is 
suitable for use as a stability indicating method for determination of Imipramine 
Hydrochloride content in Imipress Tablet 2 mg. Good linearity was established with R
2
 of 
1.000 with the mean accuracy of 99.83%. All the RSD (%) were less than 2% and 1% 
for %RSD of standard peak area and %RSD of retention time, respectively. The analytical 
method developed and validated for assay by HPLC is suitable for the accurate and precise 
determination of Imipramine Hydrochloride content in Imipress Tablet 2 mg.   
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ABSTRAK 
 
 
Imipress Tablet 25 mg adalah salah satu produk Chemical Company of Malaysia, 
Duopharma Sdn. Bhd, CCMD. Ramuan Farmaseutikal Aktif Imipramine Hidroklorida 
mengandungi 25 mg untuk sebiji pil. Pengesahan kaedah telah dijalankan dari segi 
kekhususan (memaksa degradasi), analisis plasebo, kelinearan dan pelbagai, ketepatan 
(kebolehulangan dan ketepatan perantaraan), kemantapan dan kestabilan penyelesaian. 
Kaedah ini telah terbukti linear, tepat, tahan lasak dan teguh. Kaedah HPLC adalah sesuai 
untuk digunakan sebagai kestabilan kaedah yang menunjukkan untuk penentuan kandungan 
Imipramine Hidroklorida dalam Imipress Tablet 2 mg. Kelinearan baik telah ditubuhkan 
dengan R
2
 1.000 dengan ketepatan purata sebanyak 99.83%. Semua sisihan piawai relatif 
(%) adalah kurang daripada 2% dan 1% untuk% sisihan piawai relatif luas permukaan 
untuk standard dan% sisihan piawai relatif untuk retention time. Kaedah analisis yang 
dibangunkan dan disahkan untuk cerakin oleh HPLC sesuai untuk penentuan secara tepat 
dan tepat kandungan Imipramine Hidroklorida dalam Imipress Tablet 2 mg. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background of Study and Statement of Problem 
 
1.1.1 Analytical Method Validation in Pharmaceutical Industry 
Analytical method validation is just one type of validation required during drug 
development and manufacturing. To comply with the requirement of current GMP, 
pharmaceutical companies should have an overall validation policy which 
documents how validation will be performed. This will include the validation of 
production processes, cleaning procedures, analytical method, in process control test 
procedure and computerized system. The purpose of this validation is to show that 
processes involved in the development and manufacturer of drugs, such as 
production, cleaning and analytical testing can be performed an effective and 
reproducibility manner.
[7]
 
 
The reason that validation is included in cGMP in this way is to ensure that 
quality is built in at every step and not just tested for at the end. Validation is 
intended to provide assurance of the quality for the design, manufacturer and use of 
the system or process that cannot be found by simple testing alone.
[7]  
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Once a method has been develop and validated it may be used for routine analysis 
as shown in Figure 1. However, changes may occur which make it necessary to 
evaluate whether the method is still suitable for its intended use. The change may be 
covered may result in revalidation and in some cases, redevelopment of the method 
followed by validation of the new method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The cycle of analytical method validation 
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1.1.2 Active Pharmaceutical Ingredient: Imipramine Hydrochloride 
Imipress Tablet 25 mg is one of the products of Chemical Company of 
Malaysia, Duopharma Sdn. Bhd, CCMD. The API is Imipramine 
Hydrochloride, IH, which contain 25 mg per tablet. The total weight of one 
individual Imipress Tablet 25 mg is 140 mg, which contain 115 mg of 
placebo. The placebo (also known as excipient) consist of Magnesium 
Stearate (2.1 mg), Lactose (98.578 mg), Aerocil (0.28 mg), Corn Starch (7 
mg), Polyvinylpyrrolidone (2.8 mg), Carmoisine (0.042 mg) and Promigel 
(4.2 mg).  
 
IH is a tricyclic antidepressant of the dibenzazepine group. IH also 
known as Tofranil as the trade name. 
[11]
 The molecular structure and the 
characteristic of IH had shown in Figure 2 and Table 1, respectively.  
 
 
Figure 2: Imipramine Hydrochloride 
 
 
 
 
 
4 
 
Systematic 
IUPAC name 
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-
dimethylpropan-1-amine 
Formula C19H25CIN2 
Molar Mass 316.5 g/mol 
Characters A white or slightly yellow and crystalline powder 
Solubility Freely soluble in water and in alcohol 
 
 Table 1: Imipramine Hydrochloride 
 
The metabolism of IH within the body, it is converted to desipramine which 
belong to another type of Tricyclic antidepressant.
[13] 
The side effects of IH 
include the central nervous system such as dizziness, drowsiness, headache, 
weakness, insomnia, nightmares and increase psychiatric symptoms. For 
gastrointestinal, the patient will have for dry mouth, nausea, vomiting, 
increase appetite, cramps, jaundice and taste change. Moreover, the 
symptoms and the treatment of an Imipramine overdose are largely the same 
for the other tricyclic antidepressants. Cardinal symptoms are cardiac and 
neurological disturbances. Any ingestion by children should be considered 
as serious and potentially fatal.
[11]
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1.2 Significant of Study 
This study focuses on the extraction of the IH, determination of analytical 
characteristics method and percent assay of IH in Imipress Tablet 25 mg. The 
concerns about the percent assay of this API contain in the medicine have promoted 
for the Assay studies. The use of analytical methods during development and 
manufacturing provides information on potency which can relate directly to the 
requirements of known dose; impurities which can relate to the safety profile of the 
drug, evaluation of key drug characteristics such as crystal form, drug release, drug 
uniformity and properties which can compromise bioavailability; degradation 
products methods need to be stability indicating and effect of key manufacturing 
parameter  to ensure that the production of drug substance and drug product is 
consistent.
[8]
  
 
 The validation which is performed on the method which generate the data 
needs to demonstrate that they can do so reliability and consistently. Hence, this 
method validation is use full for routine analysis in QC and to demonstrate that the 
test method of IH in Imipress Tablet 25 mg is suitable for the intended use. 
 
1.3 Objectives of the study  
An analytical method details the steps necessary to perform an analysis. This may 
include preparation of samples, standards and reagents, use of apparatus, generation 
of the calibration curve, use of the formula for calculation.
[8] 
The intention of this 
study is to validate the assay test method by high performance liquid 
chromatographic analytical method in quantitating IH in Imipress Tablet 25 mg. 
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CHAPTER 2 
  
LITERATURE REVIEW 
 
2.1  Functionality of Imipramine Hydrochloride  
The primary function of IH is to treatment of mental depressive disorder, MDD is a 
mental disorder characterized by a pervasive and persistent low mood that is 
accompanied by low self-esteem and by a loss of interest or pleasure in normally 
enjoyable activities. MDD is a disabling condition that adversely affects a person’s 
family, work or school life, sleeping and eating habits and general health.
[9]  
 
2.2 Therapeutic Uses of Imipramine Hydrochloride 
IH also used to treatment of enuresis which refers to repeated inability to control 
urination which usually limited to describing old enough to be expected to exercise 
such control.
[10] 
IH is used in the treatment of depression such as associated with 
agitation or anxiety and has similar efficacy to the antidepressant drug 
moclobemide. 
[12]  
 
2.3 Mechanism of Action of Imipramine Hydrochloride 
IH affects numerous neurotransmitter systems known to be involved in the etiology 
of depression, anxiety, enuresis and numerous other mental and physical conditions. 
IH is similar in structure to some muscle relaxants and has a significant analgesic 
effect that is very use full in some pain conditions.
[11]
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2.4 Analytical determination of Imipramine Hydrochloride 
A variety of procedures have been developed for the analysis of IH. IH has been 
determined by a variety of analytical technique such as spectrophotometry, 
spectofluorimetry, conductimetry and flow injection methods. However, many of 
these methods are limited in their applications or rather tedious and time 
consuming.
[15] 
 
HPLC has been applied to measure small amounts of IH and its major 
metabolite, desipramine in serum. A computerized GCMS technique has also been 
proposed for quantitatively determination of IH. TLC method has been used for the 
separation and detection of IH.
[14] 
Ion-SME can be applied successfully for the 
determination of IH in substance and in pharmaceuticals. 
 
The recommended method from monograph which includes United State 
Pharmacopia, USP 36 and British Pharmacopia, BP 2013 for the quantitating 
percent assay of “Imipramine Hydrochloride Tablet” is by using UV-Vis 
Spectrophotometer. This method is simple and sensitive for the determination of IH 
in Imipress Tablet 25 mg. 
 
 
 
 
 
        
Fi 
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However, in this study, the method validation of Imipramine Hydrochloride 
in Imipress Tablet 25 mg uses an in-house method as the analytical test method. The 
method originally adopted from USP 36, Volume 2 under “Imipramine 
Hydrochloride”, page 3888 (refer to Figure which using the HPLC method. This 
method considered as in-house method because the validation of IH are base on raw 
material method rather than choosing finish product method.  
 
In CCMD, there were three different departments in laboratory side which 
include QC Department, Validation Department and Stability Department. In order 
to standardize the analytical test method for IH in Imipress Tablet 25 mg for all 
departments, only one establishes method will be chosen as the validated method.  
 
For stability department, the use of HPLC method are more recommended 
because recent days, the current guidelines and regulatory requirements are very 
stringent in terms of estimation and quantification of residual impurities in any 
synthetic route or process, due to this reason the separation of all compounds in 
single run or during analysis, LC methods was taken preference over regular 
conservative mode methods of analysis. The advantages of LC methods are that the 
developed analytical methods were posses’ greater selectivity, sensitivity, accurate, 
precise and robust. Therefore, all most all methods used in Stability Department was 
developed by using HPLC.
[15]
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2.5 Method Validation in according to ICH Guidelines 
According to International Conference on Harmonization, ICH, Guidelines, the 
discussion of the validation of analytical procedures is directed to the four most 
common types of analytical procedures which are identification test, quantitative 
tests for impurities’ content, limit tests for the control impurities and quantitative 
test of the API in samples of drug substance or drug or other selected components 
(s) in the drug product.
[2]
 The parameter to be validated for assay study will base on 
the Table 2. 
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Type of analytical 
procedure 
characteristics 
Identification Testing for 
Impurities 
(quantitative Limit) 
Assay  
(dissolution, 
content and 
potency) 
Accuracy - + - + 
Precision - + - + 
      Repeatability - + - + 
      Intermediate 
Precision 
- + 
(1)
 - + 
(1)
 
Specificity + - + + 
Detection Limit - - 
(3)
 + - 
Quantitation Limit - + - - 
Linearity - + - + 
Range - + - + 
- Signifies that this characteristics is not normally evaluated 
+  Signifies that this characteristics is normally evaluated 
(1) In cases where reproducibility has been performed, intermediate precision is not 
needed. 
(2) Lack of specificity of one analytical procedure could be compensated by other 
supporting analytical procedures 
(3) May be needed in some cases. 
 
Table 2: Type of analytical procedure characteristic 
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CHAPTER 3 
 
METHODOLOGY 
 
3.1       Chemicals and reagents 
Imipramine Hydrochloride (IH) Working Standard was an in-house working 
standard. HPLC grade methanol and HPLC grade acetonitrile were purchased from 
Merck. Triethylamine, Perchloric acid (for adjusting pH) and Sodium Perchloride 
ware purchased from Fluka. Deionized water was used throughout the study. 
 
3.2 Instrumentation and chromatographic conditions 
Quantitative analysis of IH was carried out using a HPLC unit that consisted of a 
degasser, Model: Shimadzu DGU-20A3 Degasser; pump; Model: Shimadzu LC-
20AT Prominence LC; Model: Shimadzu SIL-20A Prominence, Column oven; 
Model Shimadzu CTO – 10AS VP and computer; Model: DELL. The injection was 
done by using 20 µL by auto sampler; Model: Shimadzu SIL-20A Prominence.  
 
Separation was achieved using a 5 µm Phenomenex C18, Gemini (150 mm 
length × 4.6 mm diameter). The colum temperature was set to 40°C.  The mobile 
phase was 0.06 M Sodium Perchlorate: Acetonitrile: Triethylamine (625:375:1) 
with adjustment the pH 2.0 with Perchloric Acid and the flow rate was 1.0 mL 
minˉ1. The detector was set at 269 nm. 
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3.3 Apparatus 
The apparatus used in this study were 25 mL, 50 mL, 100 mL, 200 mL and 1000 mL 
volumetric flasks; 5 mL, 6 mL, 10 mL, 15 mL pipettes; sonicator; water bath and 
beaker.  
 
3.4 Preparation of 0.06M Sodium Perchlorate 
Sodium perchorate about 7.34.64 g weight was transferred into 1000 mL volumetric 
flask. All chemical was dissolved and diluted with water and it will mix well. Mass 
was calculated using following calculation:  
 
Mole = Molarity × Volume (L) 
= 0.06 M × 1 L 
= 0.06 mole 
 
Mass  = Mole × Molecular weight 
= 0.06 mole × 136.086 g/mole 
= 3.402 g 
 
3.5 Preparation of diluent  
The diluent was water and acetonitrile with the ratio 5:3. The use of the diluent is 
for dilution. 
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3.6 Preparation of standard (Imipramine Hydrochloride Working Standard) 
30 mg of IH working standard was transferred into 100 mL volumetric flask and top 
up to volume using diluent. Then, label the solution as a Standard Solution. The 
Standard Solution contains approximately 0.3 mg/mL of IH. This Standard 
Solution was filtered through a 0.45 µm membrane filter and inject into the HPLC 
system for analysis. 
 
3.7 Preparation of sample (Imipress Tablet 25 mg) 
20 tables of Imipress Tablet 25 mg is weigh to get the average weight of this tablet. 
Grind the tablet sample into fine powder. Transfer about 168 mg (equivalent to 30 
mg of IH) of sample into a 100 mL volumetric flask. Dilute to volume with diluent, 
mix well and label it as Sample Solution. The Sample Solution contains 
approximately 0.3 mg/mL of IH. Sample Solution is filter through a 0.45µm 
membrane filter and inject once into the HPLC system for analysis. Six replicate of 
sample preparation will be performing. 
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3.8 Method Validation Procedure 
3.8.1 System Suitability  
The Standard Solution from Section  3.6 is use for the system suitability. 
The system suitability requirements for the above assay chromatographic 
procedure are shown in Table 3: 
 
Parameters  Criteria 
Tailing Factor < 2 
System precision 
i) % RSD of Standard retention time ≤ 1% 
ii) % RSD of Standard peak area ≤ 2% 
Theoretical Plate Count >2000 
 
Table 3: Parameter for system suitability 
 
3.8.2 Placebo analysis  
The placebo is prepared by mixing all the excipients and kept in an amber 
glass bottle. This placebo is a combination of all excipients for Imipress 
Tablet 25 mg as shown in Table 4. For the procedure, transfer about 138 mg 
of Placebo into a 100 mL volumetric flask, dilute to volume with diluent and 
mix well. Label this as Placebo Solution. The Placebo Solution contains 
approximately 1.38 mg/mL of Placebo. Placebo Solution is filter through a 
0.45µm membrane filter and inject into the HPLC system for analysis. One 
(1) Imipress Tablet 25 mg contains 115 mg of placebo and 25 mg of IH. For 
assay sample preparation, the sample solution contains 0.3 mg/mL of IH and 
1.38 mg/mL of placebo. 
15 
 
No Excipients Excipients (mg) (w/w) (w/w)% 
Quantity of 300 
tablets (mg) 
1 Magnesium Stearate 2.1 0.0182 1.82 5.46 
2 Aerosil 0.28 0.0024 0.24 0.72 
3 Cornstarch 7 0.0608 6.08 18.24 
4 Lactose 98.578 0.8572 85.72 257.16 
5 Polyvinylpyrrolidone 2.8 0.0243 2.43 7.29 
6 Carmoisine 0.042 0.0003 0.03 0.09 
7 Promigel 4.2 0.0365 3.65 10.95 
Total 115 0.9997 99.97 299.91 
 
Table 4: Placebo for Imipress Tablet 25 mg 
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3.8.3 Specificity (Forced Degradation) 
Forced degradation has been carried out by introducing chemical degradant 
into sample in three different routes. 
      
3.8.3.1 Control 
420 mg of powdered tablets was weight (equivalent to 75 mg of IH) and 
transferred into 50 mL volumetric flask, dissolved and diluted to volume 
with diluent. This solution was heated in water bath at 70°C for 2 hours. 
This solution was labeled as Sample Solution (a1). 5 mL of Sample 
Solution (a1) was pipette into 25 mL volumetric flask and top up to volume 
with diluent. The solution was labeled as Sample Solution (a2). This 
solution contains approximately 0.3 mg/mL of IH and 1.38 mg/mL of 
Placebo and injected with 20 µL of the resulting solution in the HPLC 
system. 
 
3.8.3.2 Acid hydrolysis 
420 mg of powdered tablets was weight (equivalent to 75 mg of IH) and 
transferred into 50 mL volumetric flask, dissolved and diluted to volume 
with 3M HCl. This solution was heated in water bath at 70°C for 2 hours. 
This solution was labeled as Sample Solution (b1). 5 mL of Sample 
Solution (b1) was pipette into 25 mL volumetric flask. For neutralization, 
add 5 mL of 3M NaOH and top up to volume with diluent. This solution was 
labeled as Sample Solution (b2). This solution contains approximately 0.3 
mg/mL of IH and 1.38 mg/mL of Placebo and injected with 20 µL of the 
resulting solution in the HPLC system. 
17 
 
3.8.3.3 Base hydrolysis 
420 mg of powdered tablets was weight (equivalent to 75 mg of IH) and 
transferred into 50 mL volumetric flask, dissolved and diluted to volume 
with 3M NaOH. This solution was heated in water bath at 70°C for 2 hours. 
This solution was labeled as Sample Solution (c1). 5 mL of Sample 
Solution (c1) was pipette into 25 mL volumetric flask. For neutralization, 
add 5 mL of 3M HCl and top up to volume with diluent. This solution was 
labeled as Sample Solution (c2). This solution contains approximately 0.3 
mg/mL of IH and 1.38 mg/mL of Placebo and injected with 20 µL of the 
resulting solution in the HPLC system. 
 
3.8.3.4 Oxidation degradation 
420 mg of powdered tablets was weight (equivalent to 75 mg of IH) and 
transferred into 50 mL was heated in water bath at 70°C for 2 hours This 
solution was labeled as Sample Solution (d1). 5 mL of Sample Solution 
(d1) was pipette into 25 mL volumetric flask and top up to volume with 
diluent. Label this as Sample Solution (d2). This solution contains 
approximately 0.3 mg/mL of IH and 1.38 mg/mL of Placebo and injected 
with 20 µL of the resulting solution in the HPLC system. 
 
The acceptance criteria that need to full fill were listed below: 
a) Analyte peak is well resolved from the other peaks, resolution > 1.5 
b) Analyte peak degraded at least 20% by one of the degradation method 
c) Peak purity index > 0.95 
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3.8.4 Linearity and Range 
Standard Stock Solution was prepared by dissolving approximately 300 
mg of Imipramine Hydrochloride in 200 mL volumetric flask with diluent 
(concentration is 1.5 mg/mL of Imipramine Hydrochloride). From this 
Standard Stock Solution, a series of five standards that span a range of 50-
150% were prepared. 
 
For 50% (0.15 mg/mL of Imipramine Hydrochloride), 5 mL of 
Standard Stock Solution was pipette into 50 mL volumetric flask and top 
up to volume with diluent. For 80% (0.24 mg/mL of Imipramine 
Hydrochloride), 4 mL of Standard Stock Solution was pipette into 25 mL 
volumetric flask and top up to volume with diluent. For 100% (0.3 mg/mL 
of Imipramine Hydrochloride), 10 mL of Standard Stock Solution was 
pipette into 50 mL volumetric flask and top up to volume with diluent. For 
120% (0.36 mg/mL of Imipramine Hydrochloride), 6 mL of Standard 
Stock Solution was pipette into 25 mL volumetric flask and top up to 
volume with diluent. For 150% (0.45 mg/mL of Imipramine Hydrochloride), 
15 mL of Standard Stock Solution was pipette into 50 mL volumetric flask 
and top up to volume with diluent. Each solution were injected three times 
into the HPLC system and record the chromatogram of each solution, at 
50%, 80%, 100%, 120% and 150% according to the method as described in 
section 3.2.  
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The peak area ratio for each level versus concentration was plotted and 
performs a linear regression using the least square method on the resulting 
curve. The acceptance criteria that need to full fill are listed below: 
a) R2 > 0.999 
b) %RSD of peak response ratio ≤ 2%. 
c) Magnitude of intercept against 100% working standard + 2%. 
 
3.8.5 Accuracy 
For accuracy, Standard Stock Solution from Section 3.4.4 was used and 
placebo standard solution was prepared by dissolving 345 mg of placebo 
into 50 ml volumetric flask with diluent (concentration is 6.9 mg/mL of 
placebo). Accuracy is assessed by performing 3 separate replicate recovery 
experiments with ‘spiked standard’ at 3 levels; 50%, 100% and 150% of the 
working concentration of Imipramine Hydrochloride.  
 
10 mL of placebo was transferred into 50 mL volumetric flask; 5 mL 
of standard stock solution was spiked into the solution and top up to volume 
with diluent. This solution contains 50% of spiked Imipramine 
Hydrochloride (0.15 mg/mL of Imipramine Hydrochloride and 1.38 mg/mL 
of placebo). 
 
10 mL of placebo was transferred into 50 mL volumetric flask; 10 
mL of standard stock solution was spiked into the solution and top up to 
volume with diluent. This solution contains 100% of spiked Imipramine 
20 
 
Hydrochloride (0.3 mg/mL of Imipramine Hydrochloride and 1.38 mg/mL 
of placebo). 
 
10 mL of placebo was transferred into 50 mL volumetric flask; 15 
mL of standard stock solution was spiked into the solution and top up to 
volume with diluent. This solution contains 150% of spiked Imipramine 
Hydrochloride (0.45 mg/mL of Imipramine Hydrochloride and 1.38 mg/mL 
of placebo). Each spiked sample was injected once into the HPLC system. 
For each sample, the sample concentration for Imipramine Hydrochloride 
using standards prepared was calculated. The percent recovery from the 
sample at each level was computed. The acceptance criteria that need to full 
fill were listed below: 
 
a) Overall mean accuracy within 100% ± 2% 
b) Overall %RSD for the measurement precision < 2% 
c) Confidence limits at 95%, µ is 100%  ±2% 
 
3.8.6 Precision  
3.8.6.1 Repeatability  
For repeatability test, 6 replicates of sample according to method as 
described in section 3.7 were prepared versus a freshly prepared standard as 
described in section 3.6. The precision between individual results was 
calculated and expressed as %RSD. The acceptance criteria that need to full 
fill were listed below: 
a) %RSD of standard retention time < 1% 
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b) %RSD for standard peak area < 2% 
c) %RSD of sample result < 2% 
d) Theoretical plate count > 2000 
e) Tailing factor < 2 
 
3.8.6.2 Intermediate Precision 
Intermediate precision was carried out by different analyst on different day, 
using different HPLC instrument and also different standard and samples 
preparation. The samples were prepared in 6 replicates according to method 
described in section 3.7. The standard solution was prepared as described in 
section 3.6. The acceptance criteria that need to full fill were listed below: 
a) %RSD of standard retention time < 1% 
b) %RSD of the standard peak area < 2% 
c) %RSD of sample result < 2% 
d) Difference of mean value for results between analysts within ± 2%. 
 
3.8.7 Robustness 
For robustness test, 6 replicates of sample were prepared according to the 
method as described in section 3.7 versus a freshly standard as described in 
section 3.6. The robustness analysis was performed under different 
conditions that vary slightly from the method parameters. Six replicate 
samples were analyzed at different flow rate, pH and different ratio of 
mobile phase, refer to Table 5: 
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Condition 
Flow 
Rate 
(mL/min) 
 
 
pH 
Mobile Phase 
Remarks 0.06M 
Sodium 
Perchlorate 
Acetonitrile Trietylamine 
A 1.0 2.0 625 375 1 Original 
B 1.2 2.0 625 375 1 
Increase flow 
rate 
C 0.8 2.0 625 375 1 
Decrease flow 
rate 
D 1.0 2.0 605 395 1 
Increase 
organic 
mobile phase 
E 1.0 2.0 645 355 1 
Decrease 
organic 
mobile phase 
F 
 
1.0 2.2 625 375 1 Increase pH 
G 
 
1.0 1.8 625 375 1 Decrease pH 
 
Table 5: Parameter for Robustness 
 
The mean results for different conditions were compared against the mean 
result for the original condition. The acceptance criteria that need to full fill 
were listed below: 
 
a) System suitability for 7 conditions is met if: 
i. Tailing factor of standard solution is < 2 
ii. Theoretical plate count of 7 injections of standard solution > 2000 
iii. Precision of 6 injections of standard solution (%RSD) <2% 
b) Difference of mean values of assay results for 6 conditions compare to 
original conditions are  not more than ± 2% 
c) % RSD of standard retention time for 7 conditions are ≤ 1% 
d) % RSD of sample assay for 7 conditions are ≤ 2% 
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3.8.8 Solution Stability 
For solution stability test, 6 replicates of sample were prepared according to 
the method as described in section 3.7 versus a freshly prepared standard as 
described in section 3.6. The samples were kept in the HPLC auto sampler at 
room temperature and re-inject after 24 hours to determine whether the 
samples are stable within 24 hours. A fresh new standard solution was 
prepared and compared to the standard solution that kept for the specific 
hours at room temperature. The mean assay value for samples after 24 hours 
using new standard was compared against mean assay value for samples at 
initial injection. The acceptance criteria that need to full fill were listed 
below: 
 
a) Difference of mean values assay results ≤ 2% 
b) Difference of peak area for freshly prepared standard solution and 
standard solution kept for specific hours is between 98% to 102% 
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CHAPTER 4 
 
RESULTS AND DISCUSSIONS 
 
4.1 Method Validation for Assay Test Method 
Method Validation is the process to confirm that the analytical procedure employed 
for a specific test is suitable for its intended use
.[2]
 Methods need to be validated or 
revalidated before their introduction into routine use, whenever the conditions 
change for which the method has been validated, whenever the method is changed 
and the change is outside the original scope of the method, when quality control 
indicates an established method is changing with time and in order to demonstrate 
the equivalence between two methods. 
[3]
 
The validity of this method has been demonstrated in laboratory experiments 
using samples and standards that are similar to the samples analyzed routinely. 
[3]
 In 
this study, the method was validated in terms of system suitability, specificity force 
degradation placebo analysis, linearity and range; accuracy, intermediate precision, 
robustness and solution stability.  
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4.2 System Suitability 
In many analytical procedures, the integral part is the system suitability testing. The 
tests are based on the concept that the equipment, electronics, analytical operations 
and samples to be analyzed constitute an integral system that can be evaluated as 
such System Suitability test parameters to be established for a particular procedure 
depend on the type of procedure being validated. 
[1] 
The system suitability results 
and chromatogram of IH Working Standard in this study were showed in Table 6 
and Chromatogram 1 (Appendix 2), respectively. 
 
Parameters Acceptance Criteria Results 
Tailing Factor ≤ 2 1.6 
System precision 
i) % RSD of Standard retention time ≤ 1% 
ii) % RSD of Standard peak area ≤ 2% 
0.4 
0.0 
Theoretical Plate Count > 2000 6676.8 
 
Table 6: The system suitability results for IH Working Standard 
 
4.2.1 Placebo analysis 
Placebo also known as excipient was the inactive ingredient in drug product. The 
placebo analysis was performed in order to investigate whether the placebo peak 
will interfere with the analyte peak or not. In this study, it shows that the placebo in 
Imipress Tablet 25 mg peak not give any interference to the IH peak 
(Chromatogram 2 and 3 in Appendix 2). 
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4.2.2 Specificity (Forced Degradation) 
Forced degradation usually involved the exposure of representative samples of drug 
product to the relevant stress conditions of heat, humidity, acid or base hydrolysis 
and oxidation. These testing play an important role in the drug development process. 
The results of force degradation studies can facilitate stability indicating method 
development, drug formulation design, selection of storage conditions and 
packaging, better understanding of potential liabilities of the drug molecule 
chemistry and solving of stability related problems. 
[4]
 
 
In this study, 3M Hydrochloric Acid and 3M Sodium Hydroxide were 
represented the chemical degradant for acid hydrolysis degradation and base 
hydrolysis degradation, respectively. While, 3% Hydrogen Peroxide was the 
chemical degradant for oxidation degradation. The result for stress conditions and it 
chromatogram were show in Table 7 and Chromatogram 4 to 7 (Appendix 2), 
respectively. From acid hydrolysis degradation condition, it shows no interference 
of IH peak. The percent (%) degradation for acid hydrolysis degradation, base 
hydrolysis degradation and oxidation degradation were 31.47%, 82.43% and 
10.96%.  The % degradation was calculated using the following formula: 
 
% Degradation = 
Ranalyte in diluent (Control) – Ranalyte in degradation 
Ranalyte in diluent (Control) 
In which; 
Ranalyte  is the peak area of IH 
Diluent act as a control  
Degradation including acid and base hydrolysis and oxidation degradation 
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Peak purity index were used to detect the presence of an impurity that is co eluting 
with the analyte peak. 
[5]
 As showed in Table 8 and Figure 6 to 9 (Appendix 2), all 
of the chromatogram shows peak purity index 1.000. Method was able to separate 
IH from possible degradation peaks. The test showed that no peak overlapped with 
IH peak after degradation. 
 
Table 7: Results for stress conditions for IH in Imipress Tablet 25 mg 
Stress Condition Acceptance criteria Results 
Acidic 3M HCl / 
70ºC/ 2 hours 
i. Analyte peak is well 
resolved from the other 
peaks, resolution > 1.5 
ii. Analyte peak degraded at 
least 20% by one of the 
degradation method 
 
i. No interference of IH peak  
ii. % degradation is 31.47% 
Basic 3M NaOH / 
70ºC/ 2 hours 
i. Analyte peak is well 
resolved from the other 
peaks which has resolution 
10.99 
ii. % degradation is 82.43% 
Oxidation 3% H2O2 / 
70ºC/ 2 hours 
i. Analyte peak is well 
resolved from the other 
peaks which have 
resolution 16.39 and 1.59  
ii. % degradation is 10.96%  
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Table 8: Peak Purity for stress conditions for IH in Imipress Tablet 25 mg 
Stress Condition Acceptance criteria Peak Purity Index 
Sample in diluent (control) > 0.95 1.000 
Sample in 3M HCl / 70ºC/ 2 hours > 0.95 1.000 
Sample in 3M NaOH / 70ºC/ 2 hours > 0.95 1.000 
Sample in 3% H2O2 / 70ºC/ 2 hours > 0.95 1.000 
 
4.2.3 Linearity and Range  
A linear relationship should be evaluated across the range of the analytical 
procedure. Linearity should be evaluated by visual inspection of a plot of signals as 
a function of analyte concentration. If there is a linear relationship, test results 
should be evaluated by appropriate statistical methods. The correlation coefficient, 
y-intercept, slope of the regression line and residual sum of squares should be 
measured. For establishment of linearity, a minimum of five concentrations is 
recommended. 
[2] 
 
The specified range is normally derived from linearity studies and depends 
on the intended application of the procedure. It is established by conforming that the 
analytical procedure provides an acceptable degree of linearity, accuracy and 
precision when applied to samples containing amount of analyte within or at the 
extremes of the specified range of the analytical procedure. 
[2] 
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The calibration curve obtained was a plot of peak area (V per seconds) as a 
function of concentration (mg/mL) as shown in Figure 4. A range of IH working 
standards at concentration ranges from 50% to 150% (5 points calibration) was 
selected in order to determine limit of linearity of the method. The chromatogram of 
each concentration can be seen in Chromatogram to 8 to 12. The data obtained, the 
calibration curve and the peak response were shown in Table 9, Table 10, Figure 4 
and Figure 5. R
2
 value of 1.000 in Figure 5 proves that it is a linear calibration curve 
and this range was suitable with the purpose of this study. The %RSD for peak 
response was 0.3% which is less than 2%. The peak response and peak response 
ratio were calculated base on following formula: 
 
Peak Response = 
Peak Area of IH 
Each Concentration of IH 
 
Peak Response 
Ratio  
= 
Peak Response of each concentration of IH 
Mean peak response of IH 
 
Table 9: IH Standard Stock use in Linearity and range 
Imipramine Hydrochloride 
Weight of standard  300.63 mg 
Concentration of standard stock solution 1.50315 mg/mL 
Purity of IH  100.00% 
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Table 10: Regression Analysis on Linearity of IH 
Level Value No. 
X = Y = Peak  Peak Response 
ratio Conc.(mg/mL) Peak Area response 
50% 1 0.15032 3561685.7 23694812.0 1.00 
80% 2 0.24050 5671178.5 23580391.5 1.00 
100% 3 0.30063 7097547.4 23608912.5 1.00 
120% 4 0.36076 8561019.9 23730776.1 1.00 
150% 5 0.45095 10659158.0 23637379.2 1.00 
  
Mean 23650454.3 1.00 
SD 61694.1655 0.0026 
%RSD 0.3 0.3 
 
 
 
Figure 4: Calibration curve for IH 
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Figure 5: Peak Response for IH 
 
Table 11: Acceptance Criteria for linearity and range 
Parameters Acceptance criteria Results 
correlation coefficient, R
2
 > 0.999 1.000 
%RSD of peak response ≤ 2% 0.3% 
 
The linearity conforms to all acceptance criteria (Table 11). Therefore the range of 
analysis was 0.15032 mg/mL to 0.45095 mg/mL for IH. 
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4.2.4 Accuracy  
The accuracy of an analytical method is the extent to which test results generated by 
the method and the true value agree. Concentration of IH involved 50% 
concentration (0.150315 mg/mL), 100% concentration (0.300630 mg/mL) and 
150% concentration (0.450945 mg/mL). The data for accuracy was tabulated in 
Table 12 and the chromatograms have shown in Chromatogram 13 to 15 in 
Appendix 2. The Found concentration (Y) of IH in mg/mL was calculated based on 
the formula from linearity and range curve: 
  y = 23666991.4444x – 4889.7713 
                      In which; 
   y =Peak Area of IH 
                                    x =Concentration of IH (mg/mL) 
 
For this accuracy analysis, the peak area for IH was obtained from HPLC analysis. 
To calculate the found concentration of IH said Y obtains from the analysis. 
Therefore,  
  Y = (y – 4889.7713) /23666991.4444 
  In which;  
   Y = Found concentration in mg/mL 
                y = Peak area of IH 
 
The method has shown to be accurate for IH determination in Imipress Tablet 25 
mg and passed all the acceptance criteria (Table 13).     
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Table 12:  Recovery results for IH (of finished product form) 
Level 
(Expected content in 
mg/mL) 
Replicate Peak Area 
Y 
(Found concentration in 
mg/mL) 
%Recovery 
(100* Y/X) 
50% 1 3545303.4 0.1495929 99.52 
X = (mg/mL) 2 3574339.3 0.1508197 100.34 
0.150315 3 3565414.3 0.1504426 100.08 
  Mean 3561685.7 0.1502851 99.98 
  %RSD 0.4 0.4 0.4 
100% 1 7099833.1 0.2997822 99.72 
X = (mg/mL) 2 7093459.0 0.2995129 99.63 
0.300630 3 7099350 0.2997618 99.71 
  Mean 7097547.4 0.2996856 99.69 
  %RSD 0.1 0.1 0.1 
150% 1 10658558.2 0.4501488 99.82 
X = (mg/mL) 2 10692079.1 0.4515652 100.14 
0.450945 3 10626836.6 0.4488085 99.53 
  Mean 10659158.0 0.4501742 99.83 
  %RSD 0.3 0.3 0.3 
 
Average mean 99.83 
SD 0.290 
%RSD 0.3 
Confidence limit 0.22 
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Table 13: Acceptance Criteria for accuracy 
Parameters Acceptance criteria Results 
Overall mean accuracy 100% ±2% 99.83 
Overall % RSD ≤ 2% 0.3% 
Confidence limits at 95%  100% ± 2% 99.62% - 100.05% 
 
 
4.2.5 Precision (Repeatability and Intermediate Precision) 
Validation of tests for assay includes an investigation of precision. 
[2]
 The measures 
standard deviation can be obtained into repeatability and intermediate precision. 
Repeatability is obtained when the analysis is carried out in one laboratory by one 
operator using one piece of equipment over a relatively short time span. 
Repeatability was assessed using six determinations at 100% of the test 
concentration (0.3 mg/mL of IH). In Chromatogram 16 and 17 (Appendix 2) shows 
the chromatogram for Imipramine Hydrochloride Working Standard and IH in 
Imipress Tablet 25 mg, respectively. The acceptance criteria for precision depend 
very much on the type of analysis. While the compound analysis in pharmaceutical 
quality a control precision of better than 1% RSD is easily achieved. 
[3] 
Table 14, 15 
and 16 show the results for repeatability. Repeatability result also have been use to 
evaluate the intermediate precision for first analyst. 
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Table 14: IH Standard use in repeatability  
Imipramine Hydrochloride 
Weight of standard  30.71 mg 
Concentration of standard  0.3071 mg/mL 
Weight of 20 Imipress Tablets 25 mg 2798.36 mg 
Purity of IH  100.00% 
 
 
Table 15:  Repeatability for standard and sample injections 
No 
Retention 
Time 
Standard 
Area 
Standard 
Retention 
Time 
Sample 
Area 
Sample 
Weight of 
sample 
Assay %Assay 
1 7.85 7144443.2 7.78 6949239.2 168.35 24.82 99.26 
2 7.82 7147948.4 7.80 6990946.0 168.50 24.94 99.77 
3 7.80 7148073.9 7.81 6958568.6 168.54 24.82 99.28 
4 7.79 7148737.2 7.83 6992220.7 168.26 24.98 99.93 
5 7.78 7148939.2 7.84 7000723.6 168.25 25.01 100.06 
6 7.76 7146315.3 7.84 6997234.1 168.25 25.00 100.01 
Mean 7.80 7147409.5 7.82 6981488.7 168.36 24.93 99.72 
SD 0.032 1722.255 0.024 21853.497 0.131 0.090 0.358 
%RSD 0.4 0.02 0.3 0.3 0.1 0.4 0.4 
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Table 16: Acceptance Criteria for repeatability 
Parameters Acceptance criteria Results 
%RSD of standard retention time < 1% 0.4% 
%RSD for standard peak area < 2% 0.0% 
%RSD of sample result < 2% 0.4% 
Theoretical plate count > 2000 6676.8 
Tailing factor < 2 1.6 
 
Intermediate Precision is a term that has been define by ICH guidelines 
[2] 
as the 
long-term variability of the measurement process and is determined by comparing 
the results of a method run within a single laboratory over a number of weeks. A 
method’s intermediate precision may reflect discrepancies in results obtained by 
different analyst, from different instruments, with different column, different sample 
and standard preparation and different day.  
 
The objective of intermediate precision validation is to verify that in the 
same laboratory the method will provide the same results once the development 
phase is over. 
[3] 
The result for first analyst was obtained from repeatability testing. 
The result for second analyst was performed from a new sample and standard which 
prepared by different analyst (Table 17 and 18). In intermediate precision, the 
comparison of two analyst’s result, the acceptance criteria were tabulated in Table 
19 and 20, respectively. The chromatograms for first and second analyst have 
shown in Chromatogram 19 to 20. The difference in % between two analysts is 
within the acceptance criteria, hence the method is rugged. 
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Table 17: IH Standard use in intermediate precision (second analyst) 
Imipramine Hydrochloride 
Weight of standard  30.69 mg 
Concentration of standard  0.3069 mg/mL 
Weight of 20 CCM Tablets  2798.36 mg 
Purity of Imipramine Hydrochloride  100.00% 
 
 
Table 18:  Intermediate precision of standard and sample injections (second analyst) 
No 
Retention 
Time 
Standard 
Area 
Standard 
Retention 
Time 
Sample 
Area 
Sample 
Weight of 
sample 
Assay %Assay 
1 8.20 7164573.2 8.05 6846088.0 168.10 24.48 97.93 
2 8.19 7166265.2 8.05 6878338.3 168.50 24.54 98.16 
3 8.10 7170866.3 8.04 6901685.0 168.40 24.64 98.55 
4 8.07 7158157.1 8.03 6849749.3 168.20 24.48 97.93 
5 8.05 7194894.2 8.03 6932935.9 169.30 24.62 98.47 
6 8.05 7143083.2 8.04 6893588.3 168.50 24.59 98.38 
Mean 8.11 7166306.5 8.04 6883730.8 168.50 24.56 98.24 
SD 0.06 15528.41 0.01 30114.97 0.42 0.07 0.27 
%RSD 0.77 0.22 0.10 0.44 0.25 0.28 0.28 
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Table 19: Influence of two different analyst, different HPLC column, different 
HPLC instrument and different day on the analysis results 
              
 
 
 
 
 
 
 
 
 
Active 
Pharmaceutical 
Ingredient, API 
Event 
Assay of 6 
samples 
(%) 
Precision 
of sample 
assay 
(%RSD) 
Difference of 
mean value 
between analysts 
(%) 
Precision of 
standard 
injections 
(%RSD) 
Precision of 
standard 
retention time 
(%RSD) 
Imipramine 
Hydrochloride 
D1.A1.I1.C1 99.72 
 
0.4 
 
(+)1.48 
0.0 0.4 
D2.A2.I2.C2 98.24 
 
0.2 
 
0.2 0.7 
Acceptance criteria < 2% ± 2%. < 2% < 1% 
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Table 20: The difference in % between 2 analysts is within the acceptance criteria, hence 
the method is rugged. 
D1 Day 1 D2 Day 2 
A1 Analyst 1 [Radiatul Nadiah] A2 Analyst 2 [Paremala] 
C1 Column 1: 
Phenomenex Gemini, C18 
4.6 x 150mm, 5m 
S/N:56680-20 
C2 Column 1: 
Phenomenex Gemini, C18 
4.6 x 150mm, 5m 
S/N:56679-18 
I1 Instrument 1 
(Shimadzu Prominence) 
High Performance Liquid 
Chromatograph – Shimadzu 
Prominence, Shimadzu PDA 
Detector and LC Solutions 
Software for instrument 
control.( L20234915442)  
I2 Instrument 2 
(Shimadzu Prominence) 
High Performance Liquid 
Chromatograph – Shimadzu 
Prominence, Shimadzu PDA 
Detector and LC Solutions 
Software for instrument control. 
(L20154604090) 
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4.2.6 Robustness 
 The evaluation of robustness should be considered during the development phase 
and depends on the type of procedure under study. It should show the reliability of an 
analysis with respect to deliberate variations in method parameters. If measurements 
are susceptible to variations in analytical conditions, the analytical conditions should 
be suitably controlled or a precautionary statement should be included in the 
procedure. One consequence of the evaluation of robustness was to ensure that the 
validity of the analytical procedure is maintained whenever used. 
[2]
 ICH guidelines 
defined robustness as a measure of the method’s capability to remain unaffected by 
small, but deliberate variations in method parameters. 
[6]
 In this study, the parameters 
that have changed were flow rate, mobile phase composition and pH in mobile phase. 
The difference in % between the different in mobile phase composition, pH and flow 
rate is within the acceptance criteria, hence the method is robust. (Refer to 
Chromatogram 21 to 35). 
 
Table 21: IH standard and sample use in robustness (flow rate) 
Imipramine Hydrochloride 
Weight of standard  30.71 mg 
Concentration of standard  0.3071 mg/mL 
Weight of sample (mg)      168.35mg,168.50mg,168.54mg,168.26mg, 
168.25mg, 168.25mg 
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       Table 22: Results of robustness for IH: Change in flow rate 
 
 
Table 23: IH standard and sample use in robustness (mobile phase composition and pH) 
Imipramine Hydrochloride 
Weight of standard  30.23 mg 
Concentration of standard  0.3023 mg/mL 
Weight of sample (mg)      168.70mg,168.20mg,168.66mg,168.21mg, 
168.23mg, 16825mg 
 
 
 
Condition 
 
Tailing of 
standard 
solution 
Theoretical Plate 
Count of 6 
injections of 
standard solution  
Precision of 6 
injections of 
standard solution  
(%RSD) 
Mean 
assay of 6 
samples 
(%) 
Different 
in assay 
(%) 
A1 1.6 6676.8 0.02 99.72 - 
B 1.5 6186.9 0.07 99.82 (-)0.10 
C 1.6 7319.9 0.07 99.87 (-)0.15 
Acceptance 
criteria 
≤ 2 > 2000 ≤ 2.0 
Different in assay 
compare against 
Condition A1 
± 2% 
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Table 24: Results of robustness for IH: Change in mobile phase composition and pH 
 
 
 
 
 
 
 
 
 
 
Condition 
 
Tailing of 
standard 
solution 
Theoretical 
Plate Count of 6 
injections of 
standard 
solution  
Precision of 6 
injections of 
standard 
solution  
(%RSD) 
Mean assay 
of 6 
samples 
(%) 
Different in 
assay (%) 
A2 1.6 6251.9 0.28 100.66 - 
D 1.6 6287.9 0.46 100.63 (+)0.03 
E 1.6 6668.8 0.54 100.66 0.00 
F 1.6 6341.1 0.38 100.96 (-)0.30 
G 1.6 6312.1 0.45 100.43 (-)0.23 
Acceptance 
criteria 
≤ 2 > 2000 ≤ 2.0 
Different in assay compare 
against Condition A2 
± 2% 
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Table 25: Acceptance Criteria for Robustness 
Parameters Acceptance criteria Results 
System suitability for 6 conditions is met if: 
a) %RSD for standard peak area 
< 2% Complies 
b) Tailing factor of standard solution < 2 Complies 
c) Theoretical plate count > 2000 Complies 
Difference of mean values of assay results for 6 
conditions compare to original conditions  
not more than ± 2% Complies 
% RSD of standard retention time for 6 
conditions 
≤ 1% Complies  
% RSD of sample assay for 6 ≤ 2% Complies 
 
4.2.7 Solution Stability 
Solution stability of the drug substance or drug product after preparation should be 
evaluated according to the test method. Most laboratories utilized auto samplers 
with overnight runs and the sample will be in solution for hours in the laboratory 
environment before the test procedure is completed. This is concern especially for 
drugs that can undergo degradation by hydrolysis, photolysis or adhesion to 
glassware. The solution stability test has been performed in order to support the 
solution stability data of the sample under normal laboratory conditions. 
[6] 
Hence, 
the sample preparation had prepared at initial stage (Day 1) and the same sample 
has been re-injected after 24 hours- final stage (Day 2). However, the standard 
preparation for IH has been prepared freshly for each preparation. Table 26 and 27; 
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and Table 28 and 29 show the results for initial stage (Day 1) and final stage (day 
2), respectively. 
 
Table 26: IH Standard use in solution stability (Day 1) 
Imipramine Hydrochloride 
Weight of standard  30.71 mg 
Concentration of standard  0.3071 mg/mL 
Weight of 20 Imipess Tablets 25 mg  2798.36 mg 
Purity of IH  100.00% 
 
Table 27:  Results for solution stability (Day 1) 
No 
Retention 
Time 
Standard 
(Day 1) 
Area 
Standard 
Retention 
Time 
Sample 
(Day 1) 
Area 
Sample 
W Assay %Assay 
1 7.85 7144443.2 7.78 6949239.2 168.35 24.82 99.26 
2 7.82 7147948.4 7.80 6990946.0 168.50 24.94 99.77 
3 7.80 7148073.9 7.81 6958568.6 168.54 24.82 99.28 
4 7.79 7148737.2 7.83 6992220.7 168.26 24.98 99.93 
5 7.78 7148939.2 7.84 7000723.6 168.25 25.01 100.06 
6 7.76 7146315.3 7.84 6997234.1 168.25 25.00 100.01 
Mean 7.80 7147409.5 7.82 6981488.7 168.36 24.93 99.72 
SD 0.032 1722.255 0.024 21853.497 0.131 0.090 0.358 
%RSD 0.4 0.02 0.3 0.3 0.1 0.4 0.4 
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Table 28: IH Standard use in solution stability (Day 2) 
  Imipramine Hydrochloride 
Weight of standard  30.86 mg 
Concentration of standard  0.3086 mg/mL 
Weight of 20 Imipress Tablets 25 mg 2798.36 mg 
Purity of IH  100.00% 
 
 
Table 29:  Results for solution stability (Day 2) 
No 
Retention 
Time 
Standard 
(Day 2) 
Area 
Standard 
Retention 
Time 
Sample 
(Day 1) 
Area 
Sample 
W Assay %Assay 
1 8.11 7134729.5 8.70 7106053.5 168.35 25.25 100.98 
2 8.11 7282552.2 8.24 7087123.4 168.50 25.16 100.62 
3 8.12 7227620.4 8.20 7219952.4 168.54 25.62 102.49 
4 8.15 7230680.7 8.19 7069441.1 168.26 25.13 100.52 
5 8.16 7220042.4 8.15 7074559.1 168.25 25.15 100.60 
6 8.16 7220295.0 8.12 7075949.4 168.25 25.15 100.62 
Mean 8.13 7219320.0 8.27 7105513.1 168.36 25.24 100.97 
SD 0.022 43499.614 0.197 52548.673 0.131 0.190 0.760 
%RSD 0.3 0.6 2.4 0.7 0.1 0.8 0.8 
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Table 30: Different in sample value 
Active Day 1 Day 2 % Difference 
IH 99.72 100.97 (-) 1.2% 
 
 Difference of peak response   = 7219320.0 × 100% 
                 7147409.5 
       = 101.0% 
 
Table 31: Difference of peak response  
Active Initial  24 hours % Difference 
IH 7219320.0 7147591.9 101.0 
        
Table 32: Acceptance Criteria for Solution Stability 
Parameters Acceptance criteria Results 
Difference in sample value with Day 1 ≤ 2% (-)1.2% 
Difference of peak response for freshly 
prepared sample solution and sample 
solution kept for specific hours 
98% to 102%. 101.0% 
 
The stability of the solution conforms to the acceptance criteria. The solution is 
stable up to 24 hours storage in HPLC auto sampler at room temperature. 
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CHAPTER 5 
 
CONCLUSION 
 
The analytical method developed and validated for assay by HPLC is suitable for 
the accurate and precise determination of Imipramine Hydrochloride content in Imipress 
Tablet 2 mg.  This method has been shown to be linear, accurate, precise, rugged and robust. 
The HPLC method is therefore suitable for use as a stability indicating method for 
determination of Imipramine Hydrochloride content in Imipress Tablet 2 mg. 
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     Appendix 1 
 
 Operating Procedure for Analytical Method Validation  
by HPLC and UPLC (Assay) 
 
1.0 Purpose  
1.1 To define the procedure to perform the analytical method validation by 
HPLC and UPLC. 
 
2.0 Scope 
2.1 This SOP covers the validation for assay analysis in pharmaceutical products 
by HPLC and UPLC method.  
2.2 The method could be compendial method, non-compendial method or in-
house method.  
 
3.0 Responsibility 
3.1.1 Validation team 
 
4.0 Frequency 
4.1 Upon development of new or upon modification of existing HPLC and 
UPLC methods for assay analysis 
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5.0 Procedures   
5.1 The typical validation characteristics considered for Assay Analysis are:  
i. Specificity 
ii. Linearity and Range 
iii. Accuracy 
iv. Repeatability 
v. Intermediate Precision 
vi. Robustness (optional) 
vii. Solution stability (optional) 
viii. System suitability 
ix. Limit of Quantification (LOQ) 
x. Limit of Detection (LOD) 
 
5.2 Assay Method Validation 
5.2.1 Specificity 
Specificity is the ability to measure accurately and specifically the analyte 
of interest in the presence of other components that may be expected to be 
present in the sample matrix. Typically these might include impurities, 
degradants, matrix, etc.  
 
5.2.1.1 Specificity determination (Placebo analysis): 
a) The analysis of a placebo (sample matrix without the analyte) 
is analyzed and the resulting system response is examined for 
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the presence of response which interferes or overlap with that 
of analyte of interest. 
b) In this case, prepare the placebo as in the manufacture 
formula.  
c) Dilute the placebo as in the Assay preparation and inject it 
into the chromatogram.  
 
 5.2.1.2 Specificity determination (Force degradation): 
a)  For full validation, force degradation study will be carried out 
for placebo, standard and sample. For verification of 
compendia method, force degradation study will be carried 
out for sample only. 
b)  The force degradation study is complete when the standard 
and sample are degraded at least 20% by one of the following 
degradation method ie: acid hydrolysis, basic hydrolysis, 
aqueous degradation, oxidation degradation, photolysis or 
thermolysis.  
 
5.2.1.3 Specificity determination (Peak purity assessment using a 
diode array detector): 
a)  The peak purity test is to show that the analyte 
chromatographic peak is not attributable to more than one 
component. 
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5.2.2 Linearity and Range 
a)   The linearity of an analytical procedure is its ability to obtain test 
results which are directly proportional to the concentration of analyte 
in the sample.  
b)    The range of an analytical procedure is the interval between the 
upper and lower concentration of analyte in the sample for which it 
has been demonstrated that the analytical procedure has a suitable 
level of precision, accuracy and linearity. 
c)    Linearity and Range determination: 
i.   Prepare minimum five (5) standard solutions with 
concentration from at least 50% to 150% of the working 
concentration. The targeted concentration of the analyte as 
described in the method must fall between this range 
ii.   If assay and impurity are performed together as one test and 
only a 100% standard is used,   linearity should cover the 
range from the reporting level of the impurities (LOQ) to 
120% of the assay specification (reference to ICH Q2 R1 
guidelines). 
iii.  For each of the minimum five (5) concentrations prepared, 
inject three (3) times for each of the solutions onto HPLC / 
UPLC system. 
iv.   The result of the mean peak area obtained for each solution is 
plotted against its corresponding theoretical concentration, 
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and a linear regression analysis is performed on the minimum 
five (5) coordinates. 
 
5.2.3 Accuracy 
a)   The accuracy is the measure of exactness of an analytical method, or 
the closeness agreement between the measured value and the value 
that is accepted either as a conventional, true value or an accepted 
reference value. 
    b)   Accuracy determination: 
1.  There are minimum three (3) methods to assess accuracy: 
i. Prepare a known standard stock solution and spike into 
the placebo at 3 levels of analyte concentrations, ie: 80%, 
100% and 120%. The spiked solutions are analyzed for 
the content of analyte against a Standard calibration curve 
obtained from Linearity and Range. 
ii. Weigh and add the known amount of analyte into placebo 
at 3 levels of analyte concentrations, ie: 80%, 100% and 
120%. The weighed analytes is analyzed against a 
Standard calibration curve obtained from Linearity and 
Range. 
iii. For standard additional method, spike in the known 
amount of analyte into finished product at 3 levels of 
analyte concentrations, ie: 80%, 100% and 120%. The 
accuracy of spiked analyte is calculated based on the 
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found concentration of analyte against theoretical 
concentration of analyte. 
 
2.   The 3 levels of analyte concentrations, ie. 80%, 100% and 
120% can be changed wherever necessary, but it should be at 
least cover 80% to 120% of the working concentration of 
analyte. 
 
3.   If the method to assess the accuracy of the analytical method is 
different  from the three (3) methods as stated in Section 
5.3.3.1(1), this method must be described  clearly in the 
individual protocol before execution. 
 
4.   For method 5.3.3.1(1a) and 5.3.3.1(1b), the amount of analyte 
recovered is calculated from the peak response of each test 
solution obtained: 
                     % accuracy =    (Peak response – intercept) x 100% 
                                    ___   Slope   
                                               Theoretical concentration 
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5.    For method 5.3.3.1(1c), the amount of analyte recovered is 
calculated based on the formula below: 
                        % accuracy = W2 x 100% 
                                                 W1 
   which,   W2 = Found concentration of analyte 
                                             W1 = Theoretical concentration of analyte 
 
  5.2.4 Precision 
a)  The precision of an analytical procedure expresses the closeness of 
agreement (degree of scatter)  between a series of measurements 
obtained from multiple sampling of the same homogeneous sample 
under the prescribed condition. 
b)  Two (2) levels : Repeatability and Intermediate precision 
 
    5.2.4.1 Repeatability: 
  a) Repeatability expresses the precision under the same operating 
conditions over a short interval of time. Repeatability is also 
termed intra-assay precision. 
      b) Repeatability determination: 
i)  Determine the precision of the method by preparing six (6) 
samples from the same lot of product. Prepare test solutions 
according to the method under validation. 
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ii) Calculate the %RSD of the six results for each analyte with 
respect to retention time and peak responses. 
 
5.2.4.2 Intermediate precision  
a) Intermediate precision refers to the results from within-lab 
variations due to random events within laboratories’ variations. 
This is to test on ruggedness for the same homogenous lot of 
sample (finish product or simulated product) by two different 
analysts which the testing is carried out on: 
 i)   Different days  
 ii)  Different standard preparation  
 iii) Different sample preparation  
 iv) Different instrument/column  
b)  Intermediate precision determination: 
i)  One (1) standard solution and six (6) sample solutions are 
prepared   by analyst 1 on the first day and analyzed according 
to the method under validation. 
ii) One (1) standard solution and six (6) sample solutions are 
prepared by analyst two on different day using the 
same/different instrument according to the method under 
validation. 
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 5.2.5 Robustness (Optional) 
a)   The robustness of an analytical procedure is a measure of its capacity 
to remain unaffected by small, but deliberate, variations in method 
parameters and provides an indication of its reliability during normal 
usage. It should be evaluated during the development phase. 
b)    Perform at least two (2) variations such as different brand of column, 
temperature, pH of buffer, ratio of mobile phase, flow rate, gradient 
curve etc. 
c)   Robustness determination: 
i)  Prepare one (1) standard solution and six (6) replicates of sample 
solutions under the condition as described in the assay method. 
 
  5.2.6   Solution Stability (Optional) 
a) The solution stability test is to check the stability of standard and 
sample solutions for specific hours at room temperature/fridge. 
b) All the test solutions from the Precision test are injected after being 
kept for specific hours at room temperature/fridge and calculated 
against freshly prepared standard. 
c) A new standard solution is prepared and compared to the standard    
solution that kept for specific hours at room temperature/fridge. 
d) If the solutions are not stable for specific hours, then the time period 
for which solutions are stable should be determined and the test 
procedure should contain a statement to this effect. 
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e) Solution stability study is not listed as the compulsory test parameters 
for analytical test method validation. However, it should be considered 
at an appropriate stage in the development of the analytical procedure. 
 
5.2.7 System Suitability 
   a)  Performance of a system is checked by performing system suitability 
tests that are designed to evaluate the performance of the entire system. 
b)   The system suitability tests are established during method development 
and validation phases to check on the performance of the system. 
c)   The performance is evaluated in terms of the following parameters: 
i)  System precision: 
Six replicates of the working concentration (100%) are injected 
into the chromatograph. 
ii)  Theoretical Plate Count (N): 
The efficiency is defined in terms of the number of theoretical 
plates (N) per column and is calculated based on equation below: 
N = 5.54 (VR
2
 / Wh2) 
   where, 
VR    = The distance along the baseline between the 
point of injection and a perpendicular dropped 
from the maximum of the peak of interest. 
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Wh   =  The width of the peak of interest at half peak 
height, measured in the same units as VR. 
iii)  Tailing factor 
The accuracy of quantitation decreases with increase in peak 
tailing because of the difficulties encountered by the integrator in 
determining where / when the peak ends and hence the 
calculation of the area under the peak.  The symmetry factor is an 
indicator of peak skewness and is calculated using the equation. 
f  =  Wx / 2d 
         where, 
        Wx  =   Peak width at 5% of peak height. 
D                =  Distance between the perpendicular dropped 
from the peak maximum and the leading edge 
of the peak at 5% of the peak height. 
iv) Capacity factor (k’) (if applicable): 
The capacity factor is a measure of where the peak of interest is 
located with respect to the void volume, ie: the elution time of 
the non-retained components (0.01% Uracil in diluents) or 
column void volume.  It is calculated using the equation: 
      TR - TO 
k’ =  ---------- 
      TO 
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where, 
       TR  =  Elution time of the analyte. 
       TO                =  Elution time of the void volume or non-
retained components. 
Normally for TO, the retention time of a 0.01% of Uracil in the 
diluent, is used. 
 v)  Resolution (if applicable): 
The resolution is to measure the quality of separations of the 
adjacent peaks.  
     
6.0 Acceptance Criteria 
 Analytical 
Test Method 
Analytical 
Performance 
Characteristics 
Acceptance criteria 
Assay Specificity 
(Placebo 
Analysis) 
No peak/s greater than noise at the +5% retention 
time window of the principal analyte peak. 
 
 
Specificity (Force 
degradation) 
 
 
i. Analyte peak must be well resolved from the 
other peaks (Resolution > 1.5 unless otherwise 
specified in the individual monograph). 
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Specificity (Peak 
purity assessment 
using a diode 
array detector) 
i. The peak purity index as obtained is greater 
than 0.95. 
 
Linearity and 
Range 
 
i. r2 > 0.999 
ii. %RSD of peak response < 2% 
iii. Magnitude of intercept against 100% working 
standard ± 2% 
Accuracy i. Overall mean accuracy within 100% ± 2% for 
ethical finished products and 100% ± 5% for 
OTC finished products or unless otherwise 
specified in the individual protocol. 
ii. Confidence limit at 95%, μ is 100% + 2% for 
ethical finished product and 100% ± 5% for 
OTC finished products or unless otherwise 
specified in the individual protocol. 
iii. % RSD for the measurement precision ≤ 2% 
for ethical finished products and ≤ 5% for OTC 
finished products or unless otherwise specified 
in the individual protocol 
Precision: 
Repeatability 
i. % RSD of the retention time for standard < 1% 
ii. %RSD of the standard peak area < 1% unless 
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otherwise specified in the individual 
monograph. 
iii. %RSD of the samples results < 2% for ethical 
finished products and < 5% for OTC finished 
products or unless otherwise specified in the 
individual protocol. 
Precision: 
Intermediate 
precision 
i. % RSD of the retention time for standard < 1% 
ii. %RSD of the standard peak area < 1% unless 
otherwise specified in the individual 
monograph. 
iii. %RSD of sample results < 2% for ethical 
finished products and < 5% for OTC finished 
products or unless otherwise specified in the 
individual protocol. 
iv. %RSD of combined results < 2% for ethical 
finished product and < 5% for OTC finished 
products or unless otherwise specified in the 
individual protocol. 
v. Difference of mean value of results between 
analysts within ±2% for ethical finished 
products and ± 5% for OTC finished products 
or unless otherwise specified in the individual 
protocol. 
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Robustness i. % RSD of the retention time for standard < 1% 
ii. %RSD of sample assay < 2% 
iii. Difference in assay results not more than ± 2%. 
iv. Achieve the system suitability requirements. 
Solution stability i. Difference in assay results ± 2% for ethical 
finished products and ± 5% for OTC finished 
products 
ii. Difference in peak response of freshly prepared 
standard solution and standard solution kept for 
specific hours ± 1% or unless otherwise 
specified in the individual protocol. 
System suitability 
 a) System 
precision 
i. %RSD of standard retention time < 1%. 
ii. %RSD of standard peak area < 1%. 
System suitability 
b) Theoretical 
Plate Count 
(N) 
The column efficiency is generally recommended 
to be more than 2000 unless otherwise specified in 
the individual monograph. 
 
System suitability 
c) Tailing factor 
i. Tailing factor is generally ≤ 2 unless otherwise 
specified in the individual protocol. 
ii. Tailing factor is 0.8 to 1.5 for BP monograph 
method 
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System suitability 
d) Capacity factor 
k’ > 2 unless otherwise specified in the individual 
monograph. 
System suitability 
e) Resolution 
 
Resolution > 2 unless otherwise specified in the 
individual monograph. 
 
 
 
67 
 
    Appendix 2 
 
Operating Procedure for the Shimadzu Prominence High Performance Liquid 
Chromatography 
 
1. Purpose 
To guide the user to operate the instrument accordingly 
 
2. Scope 
The Work Instruction applies to the description and usage of: 
a. The degasser; Model: Shimadzu DGU-20A3 Degasser 
b. The pump; Model: Shimadzu LC-20AT Prominence LC 
c. The detector; Model: Shimadzu SPD-20A Prominence uv/vis Detector 
d. The auto sampler; Model: Shimadzu SIL-20A Prominence 
e. Column oven; Model Shimadzu CTO – 10AS VP 
f. The computer; Model: DELL 
 
3. Responsibility 
3.1 Lab Technician 
 - Responsible to strictly adhere to this work instruction. 
3.2 Lab supervisor/ Executive 
 - Responsible to ensure strict adherence to this work instruction. 
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4. Procedures 
4.1 Turn ON the power of the pump A, detector, auto sampler, oven, pump B and 
computer. 
4.2 Logging into LC solution. 
4.2.1 Double-click on Analysis 1 (Instrument 1) from main menu. 
4.3 Setting up run parameters. 
 4.3.1 Select New or Open from File > New Method File / Open Method File. 
 4.3.2 Select Method > Instrument Parameters. 
 First select the Advanced > Pump, then select the Isocratic Flow / 
Binary Gradient mode. 
 Set the flow rate, upper and lower pressure limit for pump A and pump 
B pressure limit at 40.0 MPa. 
 Set the temperature required and the T. Max. at 85oC. 
 Set the time expected for the actual analysis in LC Stop Time at Data 
acquisition text box > Apply to All acquisition time. 
 When using the isocratic flow enter a stop time for the time program 
under the Time Program table and if using the Binary gradient set the 
time program under the Time program table. 
 For a Detector A, select the D2 lamp ratio and designate the required 
wavelength. 
 Click on the Download button to send the setting to the system and save 
the method. 
 Press the Instrument On/Off button on the Direct Control toolbar to 
activate the system.   
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 Open the drain valve and press the Purge sampler button to begin the 
purge cycle of the auto sampler syringe; wait until finished. 
 Close the drain valve and press the pump On/Off button. 
 From the File menu, select Personal name folder > Method file > 
Product Tested and save under the created method and save the file. 
 When the signal stabilizes, press Zero Detector A button in the Direct 
Control toolbar to the zero signal. Wait for the baseline to stabilize. 
 
4.4 Sample Injection: 
 4.4.1 Single sample injection 
 Click the Single Start button. 
 Enter the settings required for analysis and press OK. 
 Save the Method file and Data File under the same folder. 
 Once the actual retention time get set the LC Stop Time > Apply to All 
acquisition time. 
 
 4.4.2 Batch processing injection 
 Open the new Batch Processing table 
 From the File menu, click the New Batch File. 
 Click the Wizard button and enter the start vial and injection volume. 
 Press Next and select the standard location in the sequence. 
 Press Next again and enter the sample name and sample ID. 
 To automatically increment the Data file name, use parentheses around 
the starting number, i.e. Sample 001.lcd. 
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 Click the Data File and select in the same folder with Method file. 
 Change the number of standard sample vial per level and repetition 
run. 
 Select the Print report and change the Report format file in the same 
folder with Method file and Data file. 
 Click Next and enter the Sample name and Sample ID. 
 Select the Data File in the same folder with Method File and Data file. 
 Change the number of unknown sample vials in each group and 
Repetition per Run. 
 Select the Print report and change the Report format file in the same 
folder with Method file and Data file. 
 Click Next > Finish. 
 Ensure all the information appears on the Batch table. 
 Once the Batch processing is complete, click  File > Save Batch File As 
>  person name > Method File > Product tested > File Name > Save.  
( * Save the Batch Files As in the same folder with method File and Data 
File ) 
 Click Batch Start > Yes. 
 
4.5 Print a Report 
 4.5.1 Data Report  
 Click LC Postrun Analysis at the LC Solution menu. 
 Double click File > Open > Data file and double click the required data 
to open the Chromatogram. 
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 Click Wizard and set the minimum area/height and click Next > select 
the peak > Next > Next (change the name peak) > Finish. 
 Click View button on the Compound table view. 
 Click Data report. 
 Open any report format from other file and drag it to the chromatogram. 
 Adjust the User Information; 
a. Double click at user information. 
b. Click at Sample information > default and change the aquired by ( 
user name) > apply and OK. 
 Adjust the chromatogram scale. 
a. Double click at chromatogram. 
b. Change the type of chromatogram, range for X schale (time) and 
Left Y schale (Inten.) 
c. Change to User Defined in Left Y schale (Inten.) and the limitation 
from –ve integer – +ve integer. 
d. Click OK. 
 Adjust the other Item ( eg. Theoretical Plate, Tailing Factor, 
Resolution, etc.) 
a. Double click at chromatogram table. 
b. Insert the column by click at any table. 
c. Choose the item need and click Apply > OK. 
 Once the actual Data Report get, save into File > Save Report Format 
file As > Method File > Product tested > Report Format > Save. 
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 Then click Return > Apply to the method > Method File > product 
tested > Save. 
 Finally click File > Save data > Yes > OK. 
 
4.6 Cleaning of the Injection 
a. After all the analyses have been completed, remove the vials from the rack. 
b. Press the rinse sampler button on the Direct Control toolbar to begin the rinse 
cycle of the auto sampler syringe. 
 
4.7 Cleaning the HPLC 
a. Change the filtered water each time using of HPLC 
b. Change 50% Acetonitrile: Water and 100% Acetonitrile when the volume of 
this solution is less than 500ml. 
c. Remove all the Mobile Phase Bottle, flushing and storing reagent bottle from 
HPLC after using. 
 
5 Maintenance 
External cleaning of the Instrument: 
a. Dust the external surface of the instrument and the surrounding area where the 
instrument is placed. 
b. The surrounding area is also cleaned with wet cloth. 
c.   The external cleaning are done once in two weeks and monitored by Validation 
Chemists. 
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Appendix 3 
 
Chromatogram 1: Chromatogram of Imipramine Hydrochloride Working Standard 
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Chromatogram 2: Chromatogram of standard  
 
 
Chromatogram 3: Chromatogram of placebo 
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Chromatogram 4: Chromatogram of blank (diluent) versus sample solution in diluent. 
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Chromatogram 5: Chromatogram of sample solution in 3M HCl / 70ºC/ 2 hours 
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Chromatogram 6: Chromatogram of sample solution in 3M NaOH / 70ºC/ 2 hours 
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Chromatogram 7: Chromatogram of sample solution in 3% H2O2 / 70ºC/ 2 hours 
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Figure 6: Peak purity of Sample in diluent. 
 
 
Figure 7: Peak purity of Sample in 3M HCl / 70ºC/ 2 hours 
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Figure 8: Peak purity of Sample in 3M NaOH / 70ºC/ 2 hours 
 
 
Figure 9: Peak purity of Sample in 3% H2O2 / 70ºC/ 2 hours 
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Chromatogram 8: Chromatogram for at 50% of target concentration. 
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Chromatogram 9: Chromatogram for at 80% of target concentration. 
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Chromatogram 10: Chromatogram for at 100% of target concentration. 
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Chromatogram 11: Chromatogram for at 120% of target concentration. 
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Chromatogram 12: Chromatogram for at 150% of target concentration. 
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Chromatogram 13: Chromatogram for 3 samples at 50% of target concentration. 
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Chromatogram 14:  Chromatogram for 3 samples at 100% of the target concentration  
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Chromatogram 15: Chromatogram for 3 samples at 150% of the target concentration. 
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Chromatogram 16: Chromatogram of standard 
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Chromatogram 17: Chromatogram of samples 
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Chromatogram 18: Day 1, Analyst 1, Instrument 1 and Column 1_Chromatogram of 6 
Standard    Injections. 
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Chromatogram 19: Day 1, Analyst 1, Instrument 1 and Column 1_Chromatogram of 6 
replicates sample    Injections. 
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Chromatogram 20: Day 2, Analyst 2, Instrument 2 and Column 2_Chromatogram of 6 
Standard    Injections. 
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Chromatogram 20: Day 2, Analyst 2, Instrument 2 and Column 2_Chromatogram of 6 
Replicates Sample Injection. 
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Chromatogram 21: Chromatogram of 6 Injections of Standard at Condition A1 
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Chromatogram 22: Chromatogram of 6 Samples Injection at Condition A1 
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Chromatogram 23: Chromatogram of 6 Injections of Standard at Condition B 
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Chromatogram 24: Chromatogram of 6 Samples Injection at Condition B 
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Chromatogram 25: Chromatogram of 6 Injections of Standard at Condition C 
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Chromatogram 26: Chromatogram of 6 Samples Injection at Condition C 
 
 
 
 
101 
 
Chromatogram 27: Chromatogram of 6 Injections of Standard at Condition A2 
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Chromatogram 28: Chromatogram of 6 Samples Injection at Condition A2 
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Chromatogram 29: Chromatogram of 6 Injections of Standard at Condition D 
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Chromatogram 30: Chromatogram of 6 Samples Injection at Condition D 
 
 
 
 
 
105 
 
Chromatogram 31: Chromatogram of 6 Injections of Standard at Condition E 
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Chromatogram 32: Chromatogram of 6 Samples Injection at Condition E 
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Chromatogram 33: Chromatogram of 6 Injections of Standard at Condition F 
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Chromatogram 34: Chromatogram of 6 Samples Injection at Condition F 
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Chromatogram 35: Chromatogram of 6 Injections of Standard at Condition G 
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Chromatogram 36: Chromatogram of 6 Samples Injection at Condition G 
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Chromatogram 37: Chromatogram of 6 injections of standard at initial 
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Chromatogram 38: Chromatogram of 6 samples injection at initial 
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Chromatogram 39: Chromatogram of 6 injections of fresh standard  
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Chromatogram 40: Chromatogram of 6 samples injection at 24 hours 
 
